Bowery Clinic

Retatrutide vs Tirzepatide

Dr. Kyle Hoedebecke, MD
Reviewed by Dr. Kyle Hoedebecke, MD
Written by Peter Arian
Published Oct 25, 2026
Short on time?Get an AI summary of this article

Retatrutide and tirzepatide are both once-weekly injections from Eli Lilly, but retatrutide adds a third hormone target. Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those same two plus the glucagon receptor, which raises energy expenditure and burns more liver fat.

The short answer: retatrutide has produced the largest weight loss of any obesity drug tested so far — about 28% at 80 weeks in its first phase 3 trial, compared with about 22% at 72 weeks for tirzepatide. But retatrutide is still investigational and not FDA-approved, while tirzepatide is approved, widely prescribed, and available today.

Retatrutide vs tirzepatide at a glance

RetatrutideTirzepatide
Drug classTriple agonist ("triple G")Dual agonist ("twincretin")
ReceptorsGIP, GLP-1, and glucagonGIP and GLP-1
Brand namesNone yetZepbound (obesity), Mounjaro (type 2 diabetes)
DosingOnce weekly injectionOnce weekly injection
Average weight lossUp to 28.3% at 80 weeks (phase 3)Up to 22.5% at 72 weeks (phase 3)
Liver fatUp to 86% reduction in phase 2Significant reduction
Most common side effectsNausea, vomiting, diarrhea, constipationNausea, vomiting, diarrhea, constipation
FDA statusNot approved (investigational)Approved
Available todayOnly in clinical trialsYes, by prescription

What's the difference between retatrutide and tirzepatide?

The difference is one extra hormone receptor. Both drugs mimic gut hormones that regulate appetite and blood sugar:

  1. GLP-1 reduces appetite, increases fullness, and slows stomach emptying.
  2. GIP boosts insulin release after meals and appears to improve tolerability and fat metabolism when paired with GLP-1.
  3. Glucagon increases energy expenditure and pushes the liver to burn stored fat.

Tirzepatide targets the first two. Retatrutide targets all three. Glucagon on its own raises blood sugar, but paired with GLP-1 and GIP, its blood-sugar effect is offset while its fat-burning and energy-expenditure effects remain.

In practical terms, tirzepatide works mainly by helping you eat less. Retatrutide does the same, while also helping your body burn more — which is why its weight loss numbers are larger.

Retatrutide vs tirzepatide for weight loss

Retatrutide has produced more weight loss in trials than tirzepatide, though the two have not yet been compared head-to-head in a completed trial.

Retatrutide. In a 48-week phase 2 trial published in the New England Journal of Medicine, retatrutide 12 mg reduced body weight by an average of 24.2%, and many participants were still losing weight when the study ended. In TRIUMPH-1, the first phase 3 obesity trial with 2,339 participants, people taking 12 mg lost an average of 28.3% of their body weight (about 70 lbs) at 80 weeks. The 9 mg dose averaged 25.9% and the 4 mg dose 19.0%. Nearly half of people on 12 mg lost at least 30% of their body weight.

Tirzepatide. In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults, tirzepatide reduced body weight by 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses, compared with 3.1% for placebo. Among people who stayed on the 15 mg dose, average weight loss was 22.5% (about 52 lbs). In a head-to-head trial against semaglutide (Wegovy), tirzepatide produced 20.2% weight loss versus 13.7%. See our full breakdown of tirzepatide vs semaglutide.

Retatrutide 12 mgTirzepatide 15 mg
TrialTRIUMPH-1SURMOUNT-1
Duration80 weeks72 weeks
Average weight loss28.3%22.5%
Pounds lost (average)About 70 lbsAbout 52 lbs

Both figures reflect people who stayed on treatment. Keep in mind they come from separate trials with different lengths and participants, so they aren't a perfect apples-to-apples comparison. A direct head-to-head trial of retatrutide versus tirzepatide is underway.

Retatrutide vs tirzepatide for belly fat and fatty liver

Retatrutide's glucagon component makes it especially powerful against liver fat. In a phase 2 substudy published in Nature Medicine, retatrutide 12 mg reduced liver fat by 82% at 24 weeks and 86% at 48 weeks. By 48 weeks, 93% of people on the highest dose had normal liver fat levels.

Tirzepatide also significantly reduces liver fat and visceral fat as part of its overall weight loss, and is being studied for fatty liver disease. But glucagon's direct action on the liver gives retatrutide an edge in this area.

If your main goal is visceral belly fat without large overall weight loss, a growth hormone peptide such as tesamorelin is a different approach. Learn more in our guide to retatrutide vs tesamorelin.

Retatrutide vs tirzepatide for type 2 diabetes and blood sugar

Both drugs lower A1C substantially. Tirzepatide is already FDA-approved as Mounjaro for type 2 diabetes and has one of the strongest blood-sugar track records of any medication. Retatrutide has also produced large A1C reductions in trials of people with type 2 diabetes, but is not yet approved for this use.

Which has more side effects?

Both drugs share the same main side effects, which are digestive and most common while the dose is being increased:

Retatrutide's larger effect comes with somewhat more side effects at the highest dose. In TRIUMPH-1, about 11% of people on 12 mg stopped treatment because of side effects, versus 5% on placebo. Retatrutide has also been linked to a dose-related increase in heart rate that peaked around 24 weeks and then declined.

Tirzepatide's side effects are well characterized after years of use in millions of patients. In its head-to-head trial against semaglutide, fewer people stopped tirzepatide due to digestive side effects (2.7% versus 5.6%).

Does retatrutide cause more muscle loss?

Any large weight loss includes some lean mass, and more weight loss generally means more lean mass lost in absolute terms. With tirzepatide, roughly three-quarters of the weight lost is fat and one-quarter is lean mass. Full body-composition data for retatrutide are still emerging.

Whichever medication you use, resistance training and adequate protein are the best ways to protect muscle. Some people also add growth hormone peptides to support lean mass during weight loss. See our guide to the best peptides for muscle growth.

Is retatrutide FDA-approved?

No. As of October 2026, retatrutide is investigational and not FDA-approved for any condition. Lilly has reported positive phase 3 results and plans to seek approval, but it cannot be legally prescribed outside a clinical trial yet.

That matters, because "retatrutide" is widely sold online as a research chemical. These products are not made by licensed pharmacies, are not tested for purity or dose accuracy, and are labeled "not for human use." Learn why sourcing matters in our guide to research-grade peptides vs licensed pharmacies.

Tirzepatide, by contrast, is FDA-approved and available by prescription today.

Can you switch from tirzepatide to retatrutide?

Not yet outside a clinical trial. Once retatrutide is approved, switching will likely be possible under a clinician's guidance, since both drugs work through overlapping receptors. You should not take them at the same time.

If you're losing weight well on tirzepatide, there's no reason to wait. Weight lost now improves blood pressure, blood sugar, joint pain, and liver health immediately.

Which is better: retatrutide or tirzepatide?

Retatrutide may be better if you:

Tirzepatide is better if you:

For most people today, tirzepatide is the practical choice. It is the most effective approved weight-loss medication available and delivers results that were unthinkable a few years ago.

Frequently asked questions

Is retatrutide stronger than tirzepatide?

In trials, yes. Retatrutide produced about 28% average weight loss at 80 weeks, compared with about 22% for tirzepatide at 72 weeks. The two have not yet been compared in a completed head-to-head trial.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus the glucagon receptor, which increases energy expenditure and liver fat burning.

Is retatrutide available yet?

Not by prescription. Retatrutide is investigational and only available through clinical trials. Products sold online as "research" retatrutide are not regulated or intended for human use.

When will retatrutide be approved?

Lilly has completed several phase 3 trials and plans to seek FDA approval. A decision is not expected before 2027.

Is retatrutide a peptide?

Yes. Like tirzepatide and semaglutide, retatrutide is a peptide — a short chain of amino acids engineered to mimic natural hormones.

Does retatrutide have more side effects than tirzepatide?

The side effects are similar — mainly nausea, vomiting, diarrhea, and constipation — but are somewhat more common at retatrutide's highest dose. Retatrutide can also raise heart rate.

Is tirzepatide the same as Zepbound and Mounjaro?

Yes. Tirzepatide is the active ingredient in both. Zepbound is the brand approved for weight loss and sleep apnea, and Mounjaro is the brand approved for type 2 diabetes.

Can you take retatrutide and tirzepatide together?

No. They act on overlapping receptors, and combining them would increase side effects without a clear benefit.

The bottom line

Retatrutide is the most powerful weight-loss drug tested so far, but tirzepatide is the most powerful one you can actually get. Retatrutide's third receptor — glucagon — adds energy expenditure and dramatic liver-fat reduction, pushing average weight loss to around 28%. Until it's approved, tirzepatide remains the gold standard, with about 22% average weight loss and years of safety data behind it.

If you're ready to start, Bowery Clinic offers Tirzepatide after a quick online evaluation. Compare more options in our guides to peptides for weight loss and the best peptides for fat loss. See what our patients say.

References

  1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023.
  2. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.
  3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. 2026.
  4. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
  5. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025.

Continue reading

SARMs vs Peptides
SARMs vs Peptides
Bowery Clinic
Advancing peptide research through quality, innovation, and scientific excellence.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure or prevent any disease.
members@boweryclinic.com
Legal
Privacy PolicyTerms & ConditionsInstagram